Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig R Lee

Showing results (21-30 of 122) with videos related to

Pageof 13
Sort By:
Pharmacotherapy|January 2, 2023
Pharmacogenetics of P2Y<sub>12</sub> receptor inhibitorsCameron D Thomas, Alexis K Williams, Craig R Lee, et al.
Pharmacogenomics|November 7, 2009
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendationsKyle J Ellis, George A Stouffer, Howard L McLeod, et al.
Cardiovascular Drugs and Therapy|September 4, 2024
CYP2C19 Genotype-Guided Antiplatelet Therapy in Stroke Patients-Is It Ready for Prime Time?Danwei Shao, Joyce Mosha, Rajiv C Patel, et al.
Pharmacotherapy|June 25, 2003
Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individualsCraig R Lee, John A Pieper, Alan L Hinderliter, et al.
Clinical Pharmacology and Therapeutics|November 12, 2002
Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotesCraig R Lee, John A Pieper, Alan L Hinderliter, et al.
Frontiers in Cardiovascular Medicine|September 9, 2022
Evaluation of race and ethnicity disparities in outcome studies of <i>CYP2C19</i> genotype-guided antiplatelet therapyAnh B Nguyen, Larisa H Cavallari, Joseph S Rossi, et al.
Prostaglandins & Other Lipid Mediators|August 11, 2018
Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndromeAkinyemi Oni-Orisan, Sharon Cresci, Philip G Jones, et al.
Pharmacogenetics and Genomics|April 13, 2007
CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) studyCraig R Lee, Kari E North, Molly S Bray, et al.
Prostaglandins & Other Lipid Mediators|November 21, 2017
Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular diseaseNan Wang, Kimberly C Vendrov, Brian P Simmons, et al.
Clinical and Translational Science|January 17, 2025
CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional ProcedureKayla R Tunehag, Ashton F Pearce, Layna P Fox, et al.
Pageof 13

Showing results (21-30 of 122) with videos related to

Sort By:
Pageof 13
Pharmacotherapy|January 2, 2023
Pharmacogenetics of P2Y<sub>12</sub> receptor inhibitorsCameron D Thomas, Alexis K Williams, Craig R Lee, et al.
Pharmacogenomics|November 7, 2009
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendationsKyle J Ellis, George A Stouffer, Howard L McLeod, et al.
Cardiovascular Drugs and Therapy|September 4, 2024
CYP2C19 Genotype-Guided Antiplatelet Therapy in Stroke Patients-Is It Ready for Prime Time?Danwei Shao, Joyce Mosha, Rajiv C Patel, et al.
Pharmacotherapy|June 25, 2003
Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individualsCraig R Lee, John A Pieper, Alan L Hinderliter, et al.
Clinical Pharmacology and Therapeutics|November 12, 2002
Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotesCraig R Lee, John A Pieper, Alan L Hinderliter, et al.
Frontiers in Cardiovascular Medicine|September 9, 2022
Evaluation of race and ethnicity disparities in outcome studies of <i>CYP2C19</i> genotype-guided antiplatelet therapyAnh B Nguyen, Larisa H Cavallari, Joseph S Rossi, et al.
Prostaglandins & Other Lipid Mediators|August 11, 2018
Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndromeAkinyemi Oni-Orisan, Sharon Cresci, Philip G Jones, et al.
Pharmacogenetics and Genomics|April 13, 2007
CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) studyCraig R Lee, Kari E North, Molly S Bray, et al.
Prostaglandins & Other Lipid Mediators|November 21, 2017
Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular diseaseNan Wang, Kimberly C Vendrov, Brian P Simmons, et al.
Clinical and Translational Science|January 17, 2025
CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional ProcedureKayla R Tunehag, Ashton F Pearce, Layna P Fox, et al.
Pageof 13